D. Boral Capital Reiterates Buy Rating for Coya Therapeutics (NASDAQ:COYA)

Coya Therapeutics (NASDAQ:COYA)‘s stock had its “buy” rating reaffirmed by stock analysts at D. Boral Capital in a research note issued to investors on Thursday,Benzinga reports. They presently have a $18.00 price objective on the stock. D. Boral Capital’s price objective suggests a potential upside of 174.39% from the stock’s previous close.

Separately, Chardan Capital reissued a “buy” rating and set a $14.00 target price on shares of Coya Therapeutics in a report on Thursday, March 20th.

Coya Therapeutics Price Performance

Shares of NASDAQ COYA opened at $6.56 on Thursday. The stock has a market capitalization of $109.72 million, a PE ratio of -10.09 and a beta of 0.31. Coya Therapeutics has a one year low of $4.75 and a one year high of $10.24. The business’s fifty day moving average price is $6.43 and its 200-day moving average price is $6.51.

Coya Therapeutics (NASDAQ:COYA) last released its quarterly earnings data on Tuesday, March 18th. The company reported ($0.18) EPS for the quarter, beating the consensus estimate of ($0.32) by $0.14. The business had revenue of $0.20 million for the quarter, compared to analysts’ expectations of $0.10 million. As a group, equities analysts expect that Coya Therapeutics will post -1.15 EPS for the current fiscal year.

Hedge Funds Weigh In On Coya Therapeutics

A number of large investors have recently modified their holdings of COYA. Geode Capital Management LLC lifted its stake in Coya Therapeutics by 3.3% in the 3rd quarter. Geode Capital Management LLC now owns 142,309 shares of the company’s stock worth $918,000 after purchasing an additional 4,485 shares in the last quarter. Newbridge Financial Services Group Inc. purchased a new stake in shares of Coya Therapeutics in the fourth quarter worth $401,000. CM Management LLC boosted its stake in Coya Therapeutics by 11.1% during the fourth quarter. CM Management LLC now owns 160,000 shares of the company’s stock valued at $917,000 after buying an additional 15,941 shares during the period. Jane Street Group LLC purchased a new position in Coya Therapeutics during the fourth quarter worth about $74,000. Finally, Northern Trust Corp increased its stake in Coya Therapeutics by 12.2% in the 4th quarter. Northern Trust Corp now owns 28,549 shares of the company’s stock worth $164,000 after acquiring an additional 3,099 shares during the last quarter. 39.75% of the stock is currently owned by institutional investors.

Coya Therapeutics Company Profile

Coya Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.